- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Heart Failure Rates Fell From 2000-2010
The incidence rate for heart failure dropped steeply over a decade in a population-based study, and while hospitalization rates remained steady over time, causes shifted from cardiovascular to noncardiovascular.
The incidence rate for heart failure dropped steeply over a decade in a population-based study, and while hospitalization rates remained steady over time, causes shifted from cardiovascular to noncardiovascular.
Researchers at the Mayo Clinic in Rochester, Minnesota, frequently use Olmsted County in their state for epidemiological studies because medical care for the most part is provided through the Mayo system. That gives them access to most medical records from both inpatient and outpatient sources. In this study, Yariv Gerber, PhD, and colleagues tracked heart failure incidence in the county between 2000 and 2010 and outcomes at a mean 4.5 years of follow-up. The analysis broke heart failure into 2 groups: preserved (ejection fraction of 50% or greater) and reduced (less than 50%).
Read more at Cardiovascular Business: http://bit.ly/1HkQHCm
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
